Trial
NCT06691685
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Early Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Shenzhen Pregene Biopharma Co., Ltd.
Condition
Multiple Myeloma
Intervention
ESO-T01 Injection
Why stopped
The collaborator EsoBiotec was acquired by AstraZeneca.
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-22